<DOC>
	<DOCNO>NCT00390247</DOCNO>
	<brief_summary>Hypothesis In peritoneal dialysis ( PD ) patient , malnutrition , inflammation atherosclerotic cardiovascular disease commonly coexist . The triad coin `` MIA syndrome '' . Proinflammatory cytokine , tumor necrosis factor-alpha ( TNF-alpha ) , play central role pathogenesis MIA syndrome . Thalidomide selectively inhibit production TNF-alpha represent valuable anti-cytokine therapy . Specific Aim To study effect thalidomide attenuate reverse malnutrition systemic inflammation PD patient . Research Plan Design : Double-blinded randomised prospective placebo control trial . Setting : Renal unit university teach hospital . Subjects : Sixty prevalent PD patient evidence malnutrition . Interventions : Patients randomise receive either oral thalidomide 100 mg nocte placebo . Main outcome measure : Patients follow 1 year . Nutritional parameter include serum albumin , subjective global assessment , malnutrition-inflammation score , normalised protein nitrogen appearance , fat-free edema-free body mass anthropometry measurement monitor . Systemic inflammatory marker serum C-reactive protein IL-6 assayed . Hospitalisation , cardiovascular event , overall patient survival also compare study period . Expected Outcome Nutritional parameter marker systemic inflammation expect improve thalidomide therapy . The magnitude improvement nutrition , well patient morbidity , compare placebo . In Hong Kong , 80 % end-stage renal failure patient treat PD . Malnutrition , cardiovascular disease systemic inflammatory response common clinical practice . They major cause patient morbidity mortality . As readily available anti-cytokine therapy , thalidomide may represent valuable treatment MIA syndrome . The propose study provide important insight clinical benefit thalidomide treatment malnourish PD patient , account one-third dialysis population .</brief_summary>
	<brief_title>Thalidomide Treatment Malnutrition Inflammation Syndrome Peritoneal Dialysis Patients</brief_title>
	<detailed_description>Overall study design This single-center randomized placebo control study 60 prevalent PD patient . Recruitment phase take 12 month , study phase 1 year . Study code reveal end study period patient develop serious adverse reaction . Patient selection A randomize prospective study perform 60 stable PD patient . Recruitment criterion : A. clinically stable adult patient ( 18 80 year old ) PD ; B. evidence malnutrition : 1. overall subjective global assessment score &lt; 5 ; 2. malnutrition inflammation score &gt; 9 ; 3. serum albumin &lt; 35 g/L C. write patient inform consent Exclusion criterion : Patients plan elective living donor transplant within 6 month Patients plan transfer renal center within 6 month High likelihood early withdrawal study ( e.g . myocardial infarction , severe unstable coronary disease , stroke , severe liver disease within 3 month ) Active infection systemic inflammatory disease . Current malignant disease Pregnancy breast-feeding Women childbearing potential unreliable birth control method Known hypersensitivity thalidomide Baseline data include age , sex , underlie renal disease , presence diabetes , hepatitis B status , requirement helper dialysis procedure , PD regimen duration dialysis record . Interventions After initial evaluation screen visit -4 week , patient randomly assign receive either oral thalidomide 100 mg nocte placebo . Thalidomide obtain Penn Pharmaceuticals Ltd ( Gwent , UK ) 100 mg tablet , prescribe accordance publish guideline clinical use dispense thalidomide [ 34 ] . There 30 patient arm randomization . Dialysis prescription change clinical evidence underdialysis . Both patient investigator blind therapy follow assessment . Side effect record drug discontinue clinically necessary . Clinical follow Patients follow -4 ( screen ) , 0 , 4 , 8 , 12 , 18 , 24 , 30 , 36 , 44 52 week . The following clinical data document visit : Body height body weight Blood pressure Compliance thalidomide pill count Compliance dialysis exchange direct question Skin itchiness score 0 3+ , describe previously [ 31 ] Body-mass index body surface area compute . The majority patient three four 2-liter exchange per day . Blood pressure edema control standard anti-hypertensive agent and/or hypertonic dialysate . Laboratory parameters A full panel biochemical parameter monitor : Hemoglobin , plasma sodium , potassium , urea , creatinine , albumin , calcium , phosphate , alkaline phosphatase , alanine transaminase -4 , 0 , 4 , 8 , 12 , 18 , 24 , 30 , 36 , 44 52 week Fasting serum glucose , lipid iron profile 0 , 24 52 week Serum parathyroid hormone 0 52 week Serum inflammatory marker 0 , 12 , 24 , 36 52 week Inflammatory marker include serum C-reactive protein ( CRP ) , interleukin-6 ( IL-6 ) , leptin , adiponectin , tumor necrosis factor alpha ( TNF-alpha ) fibrinogen level , suggest group [ 35-38 ] . Nutritional assessment Nutritional status assess subjective global assessment ( SGA ) , comprehensive malnutrition-inflammation score ( MIS ) , normalized protein nitrogen appearance ( NPNA ) , serum albumin level , anthropometric lean body mass ( LBM ) , fat-free edema-free body mass ( FEBM ) . SGA perform -4 , 0 , 12 , 24 , 36 52 week single observer . The 4-item 7-point scoring system propose Enia et al [ 39 ] use . MIS perform -4 , 0 , 12 , 24 , 36 52 week . The calculation MIS describe previously [ 40 ] . Briefly , MIS consist 4 main part 10 component , score 0 ( normal ) 3 ( severe ) . The total score range 0 30 . FEBM PNA measure creatinine kinetics 0 , 24 52 week . A 24-hour dialysate urine collection perform . Total peritoneal Kt/V determine standard method . Residual GFR calculate average 24-hour urinary urea creatinine clearance . FEBM calculate accord formula Forbes Brunining [ 41 ] . PNA derive Randerson 's formula [ 42 ] . It normalized standard body weight . Anthropometric measurement perform 0 , 12 , 24 , 36 52 week single observer . This include bicep , tricep , subscapular supra-iliac skin fold thickness , midarm muscle circumference . Derived variable anthropometric measurement , include lean body mass ( LBM ) percentage body fat , compute standard formula [ 43 ] . Pulse wave velocity Pulse wave velocity ( PWV ) , index aortic stiffness , measure use automatic computerize recorder 0 , 24 52 week . The result analyze Complior SP program ( Artech Medical , France ) . Briefly , pressure-sensitive transducer place neck ( carotid artery ) , wrist ( radial artery ) groin ( femoral artery ) patient supine position day haemodialysis treatment put patient dialysis machine . PWV carotid-femoral carotid-radial territory calculate divide distance sensor time corresponding period separate start rise phase carotid pulse wave femoral also radial pulse wave . The procedure take 10 to15 second complete . The test perform observer eliminate effect intra-observer variation . Health-related quality life Patient acceptance satisfaction assess Chinese translation `` Kidney Disease Quality Life Short Form ( KDQOL-SFTM ) , version 1.3 '' , 0 52 week . Outcome The major outcome measure nutritional status , detail . The schedule various test summarize Appendix 2 . Secondary outcome include following : Change arterial pulse wave velocity Total number day hospital admission study period Composite cardiovascular end point : cardiovascular death , non-fatal myocardial infarction stroke , hospital admission unstable angina , coronary intervention , transient ischemic attack , low limb ischemia Number episode peritonitis study period All cause mortality Transplantation , conversion hemodialysis , recovery renal function , transfer unit also record . 4 . Potential Outcomes In Hong Kong , 80 % end-stage renal failure patient treat peritoneal dialysis ( PD ) . In 2004 , 3000 PD patient Hong Kong . Malnutrition , cardiovascular disease systemic inflammatory state common clinical practice . They major cause patient morbidity mortality . The financial implication considerable . As readily available anti-cytokine therapy , thalidomide may represent valuable treatment MIA syndrome . The propose study provide important insight clinical benefit thalidomide treatment malnourish PD patient , account one-third dialysis population . Data Analysis Statistical analysis perform SPSS Windows software version 11.5 ( SPSS Inc. , Chicago , IL ) . All data express mean +/- standard deviation unless otherwise specify . Serial change nutritional parameter , dialysis adequacy , inflammatory marker compare baseline value analysis variance multiple measure ( MANOVA ) . Serial change residual GFR examine Wilcoxon 's rank sum test Bonferroni 's correction multiple comparison skew data . Nutritional status systemic inflammatory marker one year compare 2 group Student 's t-test parametric data . Hospitalization peritonitis rate group compare Kruskal-Wallis test data highly skew . Actuarial patient survival compare logrank test Kaplan-Meier survival curve treatment group stratify variable .</detailed_description>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Malnutrition</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>A. clinically stable adult patient ( 18 80 year old ) PD ; B. evidence malnutrition : 1. overall subjective global assessment score &lt; 5 ; 2. malnutrition inflammation score &gt; 9 ; 3. serum albumin &lt; 35 g/L C. write patient inform consent Patients plan elective living donor transplant within 6 month Patients plan transfer renal center within 6 month High likelihood early withdrawal study ( e.g . myocardial infarction , severe unstable coronary disease , stroke , severe liver disease within 3 month ) Active infection systemic inflammatory disease . Current malignant disease Pregnancy breastfeed Women childbearing potential unreliable birth control method Known hypersensitivity thalidomide</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2007</verification_date>
</DOC>